Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

New England Journal of Medicine

Volumn 349, Issue 9, 2003, Pages 847-858

  Eisen, Howard J ^a,i   Tuzcu, E Murat ^j   Dorent, Richard ^b   Kobashigawa, Jon ^c   Mancini, Donna ^d   Valantine Von Kaeppler, Hannah A ^e   Starling, Randall C ^j   Sørensen, Keld ^f   Hummel, Manfred ^g   Lind, Joan M ^h   Abeywickrama, Kamal H ^h   Bernhardt, Peter ^h  

^a TEMPLE UNIVERSITY   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d New York Presbyterian Hospital Columbia University Medical Center   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Temple University School of Medicine ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; FLUINDOSTATIN; GANCICLOVIR; OKT 3; PRAVASTATIN; SIMVASTATIN; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VASCULAR DISEASE; VIRUS INFECTION;

ADULT; AGED; AZATHIOPRINE; CORONARY DISEASE; CORONARY VESSELS; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; MIDDLE AGED; REOPERATION; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 19244366021     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022171     Document Type: Article

References (39)

1. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
2. Keck BM, Bennett LE, Rosendale J, Dailey OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transpl 1999;13:35-49.
3. Julius BK, Attenhofer Jost CH, Sutsch G, et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 2000;69:847-53.
4. Azuma H, Tilney NL. Chronic graft rejection. Curr Opin Immunol 1994;6:770-6.
5. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998;17:744-53.
6. Jimenez J, Kapadia SR, Yamani MH, et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001;20:393-8. [Erratum, J Heart Lung Transplant 2001;20:803.]
7. Fang JC, Rocco T, Jarcho J, Ganz P, Mudge GH. Noninvasive assessment of transplant-associated arteriosclerosis. Am Heart J 1998;135:980-7.
8. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 1998;98:2672-8.
9. Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995;92:3445-52.
10. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995;14:632-9.
11. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999;14:140-50.
12. Morris PJ. New immunosuppressive agents. In: Morris PJ, ed. Kidney transplantation: principles and practice. 4th ed. Philadelphia: W.B. Saunders, 1994:233-43.
13. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995;17:660-5.
14. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-6.
15. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Ann Rev Immunol 1996;14:483-510.
16. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999;68:1526-32.
17. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporine, FK506, and rapamycin on graft-vessel disease. Lancet 1991;338:1297-8.
18. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991;51:486-90.
19. Schuler W, Sedrani R, Cottens S, et al. SDZ KAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
20. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, new rapamycin derivative: synergism with cyclosporine. Transplantation 1997;64:32-5.
21. Schuurman HJ, Pally C, Weckbecker G, Schuler W, Burns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999;31:1024-5.
22. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999;48:694-703.
23. Note for guidance on good clinical practice. London: European Agency for the Evaluation of Medicinal Products, January 1997. (CPMP/ICH/135/95.) (Accessed August 4, 2003, at http://www.emea.eu.int/ pdfs/human/ich/013595en.pdf)
24. World Health Organization. Declaration of Helsinki. BMJ 1996;313:1448-9.
25. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection Study Group. J Heart Transplant 1990;9:587-93.
26. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001;37:1478-92.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992;11:S90-S103.
30. Young JB. Allograft vasculopathy: diagnosing the nemesis of heart transplantation. Circulation 1999;100:458-60.
31. Liang DH, Gao SZ, Botas J, et al. Prediction of angiographic disease by intracoronary ultrasonographic findings in heart transplant recipients. J Heart Lung Transplant 1996;15:980-7.
32. Avery RK. Viral triggers of cardiac-allograft dysfunction. N Engl J Med 2001;344:1545-7.
33. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999;68:1879-83.
34. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995;59:655-61.
35. Kobashigawa JA. Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 1998;13:117-21.
36. Kobashigawa J, Miller L, Retilund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-15.
37. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
38. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
39. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002;359:1108-13.